Source-grounded facts extracted from Barinthus Biotherapeutics plc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Barinthus Biotherapeutics plc. reported quarter ended March 31, 2026 results: net income net loss attributable to its shareholders of $5.5 million, or $(0.14) per share, EPS $(0.14) per share.
“For the first quarter of 2026, the Company generated a net loss attributable to its shareholders of $5.5 million, or $(0.14) per share on both basic and fully diluted bases”
Barinthus Biotherapeutics plc. amended Amendment to the Agreement and Plan of Merger with Clywedog Therapeutics, Inc. valued at Amendment to exchange ratios and minimum cash requirements in connection with scheme of arrangement (effective 2026-02-22).
“On February 22, 2026, the Beacon, Topco, Merger Sub and Clywedog entered into the Amendment to the Agreement and Plan of Merger”
Barinthus Biotherapeutics plc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“December 30, 2025, Barinthus Biotherapeutics plc (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s American Depositary Shares (the “ADS”), each representing one ordinary share of the Company, was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Market. The notice from Nasdaq has no immediate effect on the listing of the ADSs, and t”
Gemma Brown was appointed as principal accounting officer at Barinthus Biotherapeutics plc..
“and Ms. Brown as principal accounting officer”
William Enright was appointed as principal financial officer at Barinthus Biotherapeutics plc..
“appointed William Enright, the Company’s Chief Executive Officer, as principal financial officer”
Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..
“Effective as of April 30, 2025, the Company terminated the employment of Gemma Brown as Chief Financial Officer in connection with its restructuring plan that was announced in 2025.”
Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..
“the employment of Gemma Brown effective as of April 30, 2025”
Graham Griffiths was terminated as Chief Operating Officer at Barinthus Biotherapeutics plc..
“the Company will terminate the employment of Graham Griffiths effective as of June 30, 2025”
Nadège Pelletier departed as Chief Scientific Officer at Barinthus Biotherapeutics plc..
“On November 25, 2024, Nadège Pelletier, Ph.D., notified Barinthus Biotherapeutics plc (the "Company") that she will step down as Chief Scientific Officer of the Company effective February 2, 2025.”
Graham Griffiths changed role as Chief Operating Officer at Barinthus Biotherapeutics plc..
“Effective September 1, 2024 (the “Effective Date”), Barinthus Biotherapeutics plc (the “Company”) has promoted Graham Griffiths, the Company’s Chief Business Officer, to Chief Operating Officer.”
Barinthus Biotherapeutics plc. shareholders approved Receive and approve on advisory basis the Company’s U.K. statutory directors’ compensation report for fiscal year ended December 31, 2023 at the 2024-05-10 meeting.
“To receive and approve on an advisory basis the Company’s U.K. statutory directors’ compensation report for the fiscal year ended December 31, 2023 19,030,522 4,633 16,819 3,000,133”
Barinthus Biotherapeutics plc. shareholders approved Receive the U.K. statutory annual accounts and reports for fiscal year ended December 31, 2023 and note no dividend at the 2024-05-10 meeting.
“To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2023 and to note that the Company’s directors do not recommend the payment of any dividend for the fiscal year ended December 31, 2023 19,034,966 304 16,704 3,000,133”
Barinthus Biotherapeutics plc. shareholders approved Authorize the Audit Committee to determine the Company’s auditors’ remuneration for fiscal year ending December 31, 2024 at the 2024-05-10 meeting.
“To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2024 19,035,192 171 16,611 3,000,133”
Barinthus Biotherapeutics plc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-10 meeting.
“To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 22,035,421 34 16,651 1”
Barinthus Biotherapeutics plc. shareholders approved Re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company at the 2024-05-10 meeting.
“To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 22,035,376 81 16,650 0”
Barinthus Biotherapeutics plc. shareholders approved Re-elect as a director, Robin Wright, who retires by rotation at the 2024-05-10 meeting.
“To re-elect as a director, Robin Wright, who retires by rotation in accordance with the Company’s Articles of Association 18,885,204 166,609 161 3,000,133”
Barinthus Biotherapeutics plc. shareholders approved Re-elect as a director, Alex Hammacher, who retires by rotation at the 2024-05-10 meeting.
“To re-elect as a director, Alex Hammacher, who retires by rotation in accordance with the Company’s Articles of Association 18,871,704 180,109 161 3,000,133”
Barinthus Biotherapeutics plc. shareholders approved Re-elect as a director, William Enright, who retires by rotation at the 2024-05-10 meeting.
“To re-elect as a director, William Enright, who retires by rotation in accordance with the Company’s Articles of Association 18,871,704 180,109 161 3,000,133”
Barinthus Biotherapeutics plc. reported first quarter of 2024 results: revenue nil.
“On May 13, 2024, the Company announced its financial results for the first quarter of 2024”
Barinthus Biotherapeutics plc. reported financial results for first quarter of 2024.
“On May 13, 2024, Barinthus Biotherapeutics plc (the “Company”) announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. The full text of the press release issued in connection with the update is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.